| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/25/2001 | WO2001036684A2 Mammalian toxicological response markers |
| 05/25/2001 | WO2001036677A1 Development of method for screening physiologically active pyrrole imidazole derivative |
| 05/25/2001 | WO2001036650A2 An oncolytic adenovirus |
| 05/25/2001 | WO2001036646A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036641A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 05/25/2001 | WO2001036640A2 Human fgf-21 gene and gene expression products |
| 05/25/2001 | WO2001036638A2 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036630A2 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 05/25/2001 | WO2001036629A1 Transfer compounds, the production and the use thereof |
| 05/25/2001 | WO2001036628A1 Methods of reversing drug resistance in cancer cells |
| 05/25/2001 | WO2001036626A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | WO2001036616A2 Acid nucleic construct bearing a system regulating the expression of a gene |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036602A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| 05/25/2001 | WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | WO2001036486A2 Scfv antibodies against disease associated molecules |
| 05/25/2001 | WO2001036479A1 G-protein coupled receptor |
| 05/25/2001 | WO2001036476A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | WO2001036472A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036470A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 05/25/2001 | WO2001036461A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036452A2 Heteroclitic analogs of class i epitodes |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036441A1 Antisense modulation of src-3 expression |
| 05/25/2001 | WO2001036440A1 23 human secreted proteins |
| 05/25/2001 | WO2001036433A2 Synthetic lipid-a analogs and uses thereof |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036395A1 Triazoles as farnesyl transferase inhibitors |
| 05/25/2001 | WO2001036394A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | WO2001036376A1 Novel phenylalanine derivatives |
| 05/25/2001 | WO2001036374A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 05/25/2001 | WO2001036048A1 Phorboxazole derivatives for treating cancer |
| 05/25/2001 | WO2001036007A2 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035995A2 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | WO2001035991A2 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| 05/25/2001 | WO2001035990A2 Method for enhancing t cell reactivity toward tumour antigens |
| 05/25/2001 | WO2001035989A2 Use of anti-idiotypical antibodies as vaccines against cancer |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035974A2 Aplidine treatment of cancers |
| 05/25/2001 | WO2001035970A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | WO2001035969A1 T-cells specific for polymorphic proteins on malignant cells |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035956A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035937A2 Lipid complex of alkycyclines |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | WO2001035935A2 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 05/25/2001 | WO2001035903A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001035899A2 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 05/25/2001 | WO2001010446A3 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/25/2001 | WO2001008693A3 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/25/2001 | WO2001006005A3 Diagnostic method comprising wt1 sequences |
| 05/25/2001 | WO2000073338A8 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer |
| 05/25/2001 | WO2000067793A8 Death domain containing receptor 4 |
| 05/25/2001 | WO2000061191A3 Heat stable coated colloidal iron oxides |
| 05/25/2001 | CA2720361A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | CA2392103A1 Human fgf-21 gene and gene expression products |
| 05/25/2001 | CA2392093A1 Use of nsaids for the treatment of pancreatic cancer |
| 05/25/2001 | CA2392090A1 G-protein coupled receptor |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391969A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | CA2391927A1 Novel use of antibodies as vaccines |
| 05/25/2001 | CA2391925A1 Antibodies |
| 05/25/2001 | CA2391908A1 Novel polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391885A1 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391881A1 Transfer compounds, production and use thereof |
| 05/25/2001 | CA2391622A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | CA2391530A1 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | CA2391502A1 Aplidine treatment of cancers |
| 05/25/2001 | CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | CA2391396A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | CA2391382A1 Phorboxazole derivatives for treating cancer |
| 05/25/2001 | CA2391212A1 Methods and compositions for identifying disease markers |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2390607A1 Materials and methods for detection and treatment of breast cancer |
| 05/25/2001 | CA2390548A1 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | CA2390148A1 Immunotherapy |
| 05/25/2001 | CA2390051A1 Thymidylate synthase polymorphism for predicting chemotherapeutic response |
| 05/25/2001 | CA2390031A1 Double-stranded rna receptor (dsrna-r) and methods relating thereto |
| 05/25/2001 | CA2389662A1 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | CA2389289A1 Mammalian toxicological response markers |
| 05/25/2001 | CA2388922A1 23 human secreted proteins |
| 05/25/2001 | CA2388844A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | CA2388807A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2386341A1 Heteroclitic analogs and related methods |
| 05/24/2001 | US20010001799 Anticoagulant |
| 05/24/2001 | US20010001791 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| 05/24/2001 | US20010001711 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/24/2001 | CA2290316A1 Novel source of eleutherobin and related antimitotic diterpenes |
| 05/23/2001 | EP1101820A1 Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/23/2001 | EP1101819A1 GENE Any-RF, DORMANCY REGULATORY SUBSTANCE, PROCESS FOR PRODUCING THE SAME AND CELL REGULATOR FOR VITAL CELLS |